Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Cindy, Xia"'
Autor:
Nibedita Chattopadhyay, Allison J Berger, Erik Koenig, Bret Bannerman, James Garnsey, Hugues Bernard, Paul Hales, Angel Maldonado Lopez, Yu Yang, Jill Donelan, Kristen Jordan, Stephen Tirrell, Bradley Stringer, Cindy Xia, Greg Hather, Katherine Galvin, Mark Manfredi, Nelson Rhodes, Ben Amidon
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Externí odkaz:
https://doaj.org/article/1d976cb67df14d88a310d90883ff9f3f
Autor:
Sandeepraj, Pusalkar, Xiaofei, Zhou, Yuexian, Li, Lawrence, Cohen, Jun Johnny, Yang, Suresh K, Balani, Cindy, Xia, Wen Chyi, Shyu, Chuang, Lu, Karthik, Venkatakrishnan, Swapan K, Chowdhury
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 48(3)
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted as part of a broa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::443492efeeee3c5c53a6b221b8e76974
https://pubmed.ncbi.nlm.nih.gov/31911485
https://pubmed.ncbi.nlm.nih.gov/31911485
Autor:
Sandeepraj, Pusalkar, Mihaela, Plesescu, Neeraj, Gupta, Michael, Hanley, Karthik, Venkatakrishnan, Jing-Tao, Wu, Cindy, Xia, Xiaoquan, Zhang, Swapan, Chowdhury
Publikováno v:
Cancer chemotherapy and pharmacology. 82(5)
This metabolite profiling and identification analysis (part of a phase I absorption, distribution, metabolism, and excretion study) aimed to define biotransformation pathways and evaluate associated inter-individual variability in four patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9febe64fd7b6fa4ae4e8bd72c59420c3
https://pubmed.ncbi.nlm.nih.gov/30128949
https://pubmed.ncbi.nlm.nih.gov/30128949
Autor:
Neeraj, Gupta, Steven, Zhang, Sandeepraj, Pusalkar, Mihaela, Plesescu, Swapan, Chowdhury, Michael J, Hanley, Bingxia, Wang, Cindy, Xia, Xiaoquan, Zhang, Karthik, Venkatakrishnan, Dale R, Shepard
Publikováno v:
Investigational New Drugs
Summary This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In Part A of the study, patients received a single 4.1 mg oral solution dose of [14C]-ix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f3cdf5932f53849f90734b827c3a1e3
https://pubmed.ncbi.nlm.nih.gov/28932928
https://pubmed.ncbi.nlm.nih.gov/28932928
Publikováno v:
Cancer Chemotherapy & Pharmacology; Jun2008, Vol. 62 Issue 1, p117-122, 6p, 1 Diagram, 2 Charts, 2 Graphs
Publikováno v:
Frontiers in Pharmacology; 2024, p1-16, 16p
Publikováno v:
Frontiers in Pharmacology; 2023, p1-7, 7p
Publikováno v:
Drug Metabolism Reviews. Nov2015 Supplement, Vol. 47, p6-33. 28p.
Publikováno v:
AAPS Journal; May2020, Vol. 22 Issue 3, p1-10, 10p
Publikováno v:
Drug Metabolism Reviews. Nov2011 Supplement 2, Vol. 43, p37-211. 175p.